Brought to you by 
Amgen, Janssen team up in trial collaboration for myeloma
15 Oct 2021
Executive Summary
Janssen Biotech Inc. and Amgen Inc.'s Onyx Pharmaceuticals Inc. entered into a trial collaboration agreement to evaluate the efficacy and safety of Janssen's Darzalex (daratumumab) in combination with Onyx's Kyprolis carfilzomib and dexamethasone as a treatment for cancer.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Trial Collaborations
- R&D (No Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Amgen, Janssen team up in trial collaboration for myeloma
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice